Clinical Trial Update: A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

BridGene Biosciences' BGC515 capsules are in a Phase 1 trial for advanced solid tumors, including malignant mesothelioma and epithelioid hemangioendothelioma, w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelioid Hemangioendothelioma
• Malignant Mesothelioma

Drugs mentioned

• BGC515

Snippet

Sponsor: BridGene Biosciences Inc. | Conditions: Mesothelioma, Epithelioid Hemangioendothelioma(EHE) | Phase 1 | Status: RECRUITING